ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects

Nephrology Dialysis Transplantation

Volumn 22, Issue 2, 2007, Pages 597-601

  Keidar, Shlomo ^a,b   Strizevsky, Alexander ^a   Raz, Ayelet ^a   Gamliel Lazarovich, Aviva ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

ACE2; Angiotensin; Hypertension; Macrophages; RAAS

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; CELL PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; LEUCINE; PHENYLALANINE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HYPERTENSION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN HYDROLYSIS; STATISTICAL SIGNIFICANCE;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; MACROPHAGES; MALE; PEPTIDYL-DIPEPTIDASE A;

EID: 33846702076     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl632     Document Type: Article

References (27)

1. Dostal DE, Baker KM. The cardiac renin-angiotensin system: Conceptual, or a regulator of cardiac function? Circ Res 1999; 85: 643-650
2. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9
3. Turner AJ, Tipnis SR, Guy JL, Rice G, Hooper NM. ACEH/ ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 2002; 80: 346-353
4. Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828
5. Ferrario CM, Chappell MC, Tallant EA, Brosniham KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-541
6. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 699-705
7. Yagil Y, Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 2003; 41: 871-873
8. Keidar S, Gamliel-Lazarovich A, Kaplan M et al. Mineralcorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 2005; 97: 946-953
9. Ronca-Testoni S. Direct spectrophotometric assay for angiotensin-converting enzyme in serum. Clin Chem 1983; 29: 1093-1096
10. Huang L, Sexton DJ, Skogerson K et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 2003; 278: 15532-15540
11. Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572
12. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682-1686
13. Julius S, Nesbitt SD, Egan BM et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697
14. Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48: 833-838
15. Esler M, Julius S, Zweifler A et al. Mild high-renin essential hypertension: Neurogenic human hypertension? N Engl J Med 1977; 296: 405-411
16. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-350
17. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-1474
18. Gurley SB, Allred A, Le TH et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116: 2218-2225
19. Tikellis C, Cooper ME, Bialkowski K et al. Developmental expression of ACE2 in the SHR kidney: A role in hypertension? Kidney Int 2006; 70: 34-41
20. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: A renoprotective combination? Hypertension 2004; 43: 1120-1125
21. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-2610
22. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxipeptidase. J Biol Chem 2002; 277: 14838-14843
23. Zisman LS, Keller RS, Weaver B et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003; 108: 1707-1712
24. Lee MA, Bohm M, Paul M, Ganten D. Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation 1993; 87: IV7-IV13
25. Dzau VJ, Bernstein K, Celermajer D et al. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc Drugs Ther 2002; 16: 149-160
26. Riviere G, Michaud A, Breton C et al. Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. Hypertension 2005; 46: 1-6
27. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens 2002; 20: 593-596